Lipigon Pharmaceuticals AB (publ) (LPGO.ST) Research

Lipigon Pharmaceuticals AB (publ), a company based in Umeå, Sweden, specializes in the development of therapeutic solutions for lipid-related disorders. Their innovative pipeline includes the Lipisense project, designed to address severe hypertriglyceridemia (SHTG) and familial chylomicronemia syndrome (FCS). Additionally, they are advancing a gene therapy program for lipodystrophy, a rare condition marked by atypical fat distribution throughout the body. Their work also extends to developing treatments for dyslipidemia, a general lipid imbalance, and an RNA drug candidate for acute respiratory distress syndrome (ARDS). In a strategic collaboration with HitGen Inc., Lipigon is also involved in creating small molecule therapies aimed at dyslipidemia, cardiovascular ailments, and other metabolic conditions. The firm, established in Umeå, Sweden, began its operations in 2010.

Market snapshot

Symbol
LPGO.ST
Price
$0.00
Day change
-44.44%
Market cap
$908.9K
P/E ratio
-0.01x
52-week range
0.0011-0.1935
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • AcouSort AB (publ) (ACOU.ST)
  • Alligator Bioscience AB (publ) (ATORX.ST)
  • ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST)
  • Scandinavian Real Heart AB (Publ) (HEART.ST)
  • Newbury Pharmaceuticals AB (publ) (NEWBRY.ST)
  • OncoZenge AB (publ) (ONCOZ.ST)
  • ScandiDos AB (publ) (SDOS.ST)
  • Simris Alg AB (publ) (SIMRIS-B.ST)

Open Lipigon Pharmaceuticals AB (publ) (LPGO.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.